Drugs / dolastatin 10
dolastatin 10
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00003693 | Dec 1998 → Oct 2001 | leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT00003914 | Aug 1999 → Aug 2002 | kidney cancer | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00003778 | Apr 1999 → Jul 2000 | ovarian cancer, soft tissue sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00003677 | Feb 1999 → Jan 2002 | pancreatic adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003557 | Jan 1999 → Jun 2000 | extrahepatic bile duct carcinoma, gallbladder cancer | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00003626 | Oct 1998 → Dec 1999 | prostate cancer | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00005579 | Jun 1998 → Feb 2003 | leukemia, lymphoma | University of Vermont | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dolastatin-10 | “A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer” NCT00003557 ↗8“Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects.” PMID 11106233 ↗ Nov 2000 |
| Known as | Dolostatin 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL39541 ↗ |
| Known as | NSC 376128 | “Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma” NCT00003677 ↗1“A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer” NCT00003557 ↗ |
| Modality | Peptide | “Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects.” PMID 11106233 ↗ Nov 2000 |
| Route | Intravenous | “Patients receive dolastatin 10 IV bolus every 3 weeks.” NCT00003557 ↗ |